UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2025 (Report No. 3)

Commission file number: 001-40753

ICECURE MEDICAL LTD.
(Translation of registrant's name into English)

7 Ha'Eshel St., PO Box 3163
<u>Caesarea, 3079504 Israel</u>
Address of principal executive office)

(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:
⊠ Form 20-F ☐ Form 40-F
<u>CONTENTS</u>
On August 20, 2025, IceCure Medical Ltd. (the "Company") convened its Annual and Special General Meeting of Shareholders (the "Meeting").
At the Meeting, a quorum was present and the shareholders of the Company voted upon and approved, by the applicable required majority, all agenda items that were described in the Company's proxy statement for the Meeting, which were included in Exhibit 99.2 to the Company's Report of Foreign Private Issuer on Form 6-K that the Company furnished to the Securities and Exchange Commission ("SEC") on July 16, 2025 (the "Proxy Statement").
This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company's Registration Statements on Form F-3 (Registration Nos. 333-267272 and 333-258660) and Form S-8 (Registration Nos. 333-270982, 333-264578, 333-262620, and 333-281587), filed with the SEC, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
1
<u>SIGNATURES</u>
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
IceCure Medical Ltd.

By: /s/ Eyal Shamir
Name: Eyal Shamir
Title: Chief Executive Officer

Date: August 20, 2025